News

Paolo Savoca discusses how NexaBiome is integrating AI and machine learning in phage selection to improve host matching and advance personalized phage therapy.

First public hospital in the European Union, Hospices Civils de Lyon authorized to manufacture GMP therapeutic phages, marks a major milestone in the advancement of regulated phage therapy across Europe.

NexaBiome has received continued funding from Scotland’s national economic development agency, to accelerate its breakthrough bacteriophage technology for the treatment of Diabetic Foot Infections (DFIs).

Jason Clark, Director and CSO of NexaBiome breaks down 3 common misconceptions about phage therapy; regulatory pathways, scalability, and efficacy. Learn how AI, new MHRA guidelines, and clinical success are …

BiomX has dosed the first Cystic fibrosis (CF) patient in its Phase 2b trial of BX004, a phage therapy for chronic Pseudomonas aeruginosa infections. Early results showed 14.3% of patients …

Phage therapy in the UK: Regulatory considerations and guidelines. Read about the latest considerations and regulations on phage therapy.

TechnoPhage PHAXIAM Therapeutics partnership will expand GMP phage availability for individualized phage therapy, providing physicians with comprehensive GMP phages and enhancing treatment options for drug-resistant bacterial infections.

The latest developments focused on Phage therapy and products, from partnerships and mergers and regulatory breakthroughs. The future of phage therapy holds immense promise, with collaborations driving innovation and transformative …

NexaBiome JAFRAL partnership will enable phage production capacity to be hundredfold, creating the potential to treat millions of patients with phage-based therapies.

NexaBiome was an expert witness at the inquiry into the antimicrobial potential of bacteriophages in the UK to combat AMR – with some strong recommendations to the government and the …